Business Standard

India begins human trials of Coviaxin, hoping for Covid-19 vaccine success

Private and state-owned hospitals will test the potential vaccine on volunteers, aged between 18 and 55

Human trials of Coviaxin begin across India as the nation awaits vaccine
Premium

Phase I of the vaccine trial will be done on healthy people, aged between 18 and 55 years, having no co-morbid conditions

BS Web Team New Delhi
Human trials for Covaxin, one of the first potential vaccines developed in India in the fight against Covid-19, is underway in 12 centres across the country.

Covaxin is derived from a strain of the SARS-CoV-2, the virus that causes Covid-19, and it was isolated at the Pune-based National Institute of Virology (NIV). The Indian Council of Medical Research (ICMR) and Bharat Biotech are jointly working for the preclinical as well as clinical development of this vaccine. It has already received approval for phase-I and phase- II human trials by the Drug Controller General of India (DGCI).

The ICMR had identified

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jul 21 2020 | 10:26 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com